Oncoimmune, Inc.

University of Michigan

Oncoc4, Inc.

Children's National Medical Center

Children's Research Institute, Children's National Medical Center

University System of Maryland

Oncolmmune, Inc.

Yang Liu

Pan Zheng

Martin Devenport

Wei Wu

Yin Wang

Xincheng Zheng

Yihao Zheng

Mingyue Liu

Yan Liu

Jeffrey Stephen Plott

Fei Tang

Luis Emilio Savastano

Albert Jau-Min Shih

Xuexiang Du

Sami N Malek

Guo-Yun Chen

Steve Kunkel

Xi Chelsea Chen

Michael R Bailey

Albert J Shih

Hitinder S Gurm

Mingyan Liu

Manish Karir

Jing Zhang

Yao Liu

Yan Zhang

Zhihong Xue

Peiying Ye

Hung-Yen Chou

Rhonda Flores

Christopher Bailey

Tao Zuo

Runhua Liu

Lizhong Wang

Xing Chang

Xi Cheng

Ning Li

Plott Jeffrey Stephen

Pan Zeng

This invention relates to CTLA-4 protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy.

CD80 and CD86 binding protein compositions and uses thereof

An actuated telescoping system for navigation within a vascular lumen and thrombectomy of a thrombus. The system includes a tubular catheter member having an open distal end defining a catheter lumen, a vacuum source, a rotational drive system, a flexible shaft having a channel coupled to the rotational drive system for rotational movement in response thereto, and an optional guidewire selectively inserted at least partially within the flexible shaft. The flexible shaft is at least partially disposed within the tubular catheter member configured for uncoupled rotational and translational motion therein and to optionally define a corkscrew motion in response to rotational driving force by the drive system that results in formation of hydrodynamic vortices within the catheter lumen. The telescoping system can be capable of reversibly transitioning between navigation and thrombectomy modes by differentially disposing and actuating the components and enable faster, more efficient and simpler removal of thromboembolic material.

Hydrodynamic vortex aspiration catheter

Provided herein are anti-CD24 antibodies that selectively bind human CD24 expressed in cancer cells, but not human CD24 expressed in non-cancerous cells, and the use of such antibodies in cancer therapy.

Anti-CD24 compositions and uses thereof

This invention relates to anti-CTLA-4 antibody compositions that bind to the human CTLA-4 molecule, and the use of the compositions in cancer immunotherapy and for reducing autoimmune side effects compared to other immunotherapeutic agents.

Mutant anti-CTLA-4 antibodies with improved immunotherapeutic effect but attenuated adverse effects

The present invention relates to the use of a CD24 protein for preventing or treating relapse of a cancer in a subject. The present invention also relates to the use of a CD24 protein for reducing cancer stem cell activity.

Methods of use of CD24 for the prevention and treatment of leukemia relapse

This invention relates to compositions of chimeric and humanized antibodies that bind to the human CTLA4 molecule and their use in cancer immunotherapy and for reduction of autoimmune side effects compared to other immunotherapeutic agents.

Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof

The present invention relates to the use of a CD24 protein for treating Systemic Lupus Erythematosus (Lupus, SLE).

Methods of use of soluble CD24 for treating lupus nephritis

The present invention relates to a CD24 protein for treating immune-related adverse events (irAEs) associated with cancer immunotherapy. Provided herein is a method of treating, mitigating, minimizing, or preventing immunerelated adverse events (irAEs) associated with a cancer immunotherapy by administering a CD24 protein to a subject in need thereof. The irAE may be diarrhea or another gastrointestinal disorder, pure red cell aplasia, microcytic anemia, lupus, autoimmune nephritism, autoimmune hepatitis, pneumonitis, myocarditis, pericarditis, endocrinopathy, Addison's disease, hypogonadism, Sjogren's syndrome, or type I diabetes. The CCD24 protein may comprise a mature human CD24 or a variant thereof.

Methods of use of soluble CD24 for treating immune related adverse events in cancer therapies

This invention relates to cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) protein compositions and their use in the mitigation of autoimmune adverse events associated with cancer immunotherapy. Specifically, the disclosure provides a CTLA-4 protein comprising a mutant extracellular domain of CTLA-4, wherein the CTLA-4 protein exhibits reduced binding to an anti-CTLA-4 antibody as compared to a wild-type extracellular domain of CTLA-4, wherein the anti-CTLA-4 antibody has anti-cancer immunotherapeutic activity.

A liposomal drug formulation for treating a disease in a patient characterized by overexpression of HIF-1&#x3b1; and/or HIF-2&#x3b1; includes a plurality of liposomes in a pharmaceutically acceptable carrier. The liposomes encapsulate echinomycin and are made from a peglyated phospholipid, a neutral phosphoglyceride, and a sterol. The PEGylated liposomes may be used to treat proliferative diseases, leukemia, cancer, autoimmune diseases and graft-versus-host disease.

Echinomycin formulation, method of making and method of use thereof

The present invention relates to the use of a CD24 protein for lowering low-density lipoprotein cholesterol levels, treating and preventing atherosclerosis, and for reducing risk of cardiovascular disease.

Use of CD24 for lowering low-density lipoprotein cholesterol levels

Growing community of inventors

Ann Arbor, MI, United States of America

Yang Liu